Clinical Analysis of Mitoxantrone Liposome in the Treatment of Children with High-Risk Acute Myeloid Leukemia
10.19746/j.cnki.issn1009-2137.2024.02.006
- VernacularTitle:含米托蒽醌脂质体方案治疗高危儿童急性髓系白血病的临床分析
- Author:
Yu-Qing JIAO
1
;
Hao XIONG
;
Zhi CHEN
;
Li YANG
;
Fang TAO
;
Ming SUN
;
Shan-Shan QI
;
Wen-Jie LU
;
Zhuo WANG
;
Yu DU
;
Lin-Lin LUO
Author Information
1. 武汉科技大学医学院,湖北武汉 430065
- Keywords:
mitoxantrone liposome;
acute myeloid leukemia;
idarubicin;
children
- From:
Journal of Experimental Hematology
2024;32(2):365-369
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the safety and efficacy of mitoxantrone liposome in the treatment of children with high-risk acute myeloid leukemia(AML).Methods:The children with high-risk AML who received the mitoxantrone liposome regimen at Wuhan Children's Hospital from January 2022 to February 2023 were collected as the observation group,and the children with high-risk AML who received idarubicin regimen were enrolled as controls,and their clinical data were analyzed.Time to bone marrow recovery,the complete remission rate of bone marrow cytology,the clearance rate of minimal residual disease,and treatment-related adverse reactions were compared between the two groups.Results:The patients treated with mitoxantrone liposome showed shorter time to recovery of leukocytes(17 vs 21 day),granulocytes(18 vs 24 day),platelets(17 vs 24 day),and hemoglobin(20 vs 26 day)compared with those treated with idarubicin,there were statistical differences(P＜0.05).The effective rate and MRD turning negative rate in the observation group were 90.9％and 72.7％,respectively,while those in the control group were 94.1％and 76.4％,with no statistical difference(P＞0.05).The overall response rate of the two groups of patients was similar.Conclusion:The efficacy of mitoxantrone liposome is not inferior to that of idarubicin in children with high-risk AML,but mitoxantrone liposome allows a significantly shorter duration of bone marrow suppression and the safety is better.
